

Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")

Notice of Annual General Meeting

York, U.K. 21 October 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces that its Annual General Meeting ('AGM') will be held on Tuesday 19 November 2024 at 10:00 GMT at the Company's offices at York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.

Printed copies of the Notice of the AGM and 2024 Annual Report have been posted to registered shareholders who have elected to receive paper communications and will shortly be available on the Company's website:
<https://www.abingdonhealth.com/investors/documents-and-reports/>

Enquiries:

Abingdon Health plc

Chris Yates, Chief Executive Officer
Chris Hand, Executive Chairman

www.abingdonhealth.com/investors/
Via Walbrook PR

Zeus Capital (Sole Broker and Nominated Adviser)

Chris Fielding / Isaac Hooper / Alexandra Campbell-Harris (Corporate Finance)
Fraser Marshall (Corporate Broking)

Tel: +44 (0)20 3829 5000

Walbrook PR (Media & Investor Relations)

Paul McManus / Alice Woodings
Phillip Marriage

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
+44 (0)7867 984 082

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.

The Company's [CDMO division](#) offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

Abingdon's regulatory services companies, [Compliance Solutions \(Life Sciences\)](#) and [IVDeology](#), provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The [Abingdon Simply Test](#) e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAQKDBQBBDDFKB